nach oben

International Urology and Nephrology

Erschienen in:

01.04.2014 | Urology - Original Paper

The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms

verfasst von: Zhaoyi Li, Ruipeng Hou, Jian Li

Erschienen in: International Urology and Nephrology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We compared the safety and efficacy of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate (PVBT/PVP) in patients with bladder tumor and bladder outlet obstruction caused by benign prostate hyperplasia (BPH).

Methods

Sixty-two patients with bladder tumor were enrolled in our prospective and randomized trial. A total of 37 men underwent simultaneous transurethral PVBT/PVP, and 25 patients underwent PVBT alone. The clinicopathological parameters and the recurrence of bladder tumor on the bladder neck/prostatic fossa were evaluated in all patients.

Results

Clinicopathological parameters of both groups were similar. The rates of recurrence, progression and tumor recurrence of bladder neck/prostatic fossa were 16.0, 4.0 and 4.0 % in the simultaneous resection group, and 18.9, 5.4 and 8.1 % in the group PVBT, respectively. No statistically significant differences were found between the two groups (P > 0.05).

Conclusions

Simultaneous PVBT/PVP may help decrease the overall recurrence rate and tumor recurrence in bladder neck/prostatic fossa. PVBT/PVP can be performed effectively and safely in patients with bladder tumor and BPH.

Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30PubMedCrossRef

Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–467 discussion 475–467PubMedCrossRef

Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415PubMedCrossRef

Hinman F Jr (1956) Recurrence of bladder tumors by surgical implantation. J Urol 75:695–696PubMed

Gomez Sancha F, Bachmann A, Choi BB, Tabatabaei S, Muir GH (2007) Photoselective vaporization of the prostate (GreenLight PV): lessons learnt after 3500 procedures. Prostate Cancer Prostatic Dis 10:316–322PubMedCrossRef

Chen CH, Chiang PH, Chuang YC, Lee WC, Chen YT (2010) Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. Urology 75:658–663PubMedCrossRef

Nargund VH, Tanabalan CK, Kabir MN (2012) Management of non-muscle-invasive (superficial) bladder cancer. Semin Oncol 39:559–572PubMedCrossRef

Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479PubMed

Djavan B, Nickel JC, de la Rosette J, Abrams P (2002) The urologist view of BPH progression: results of an international survey. Eur Urol 41:490–496PubMedCrossRef

10.

Kadlubar FF, Dooley KL, Teitel CH, Roberts DW, Benson RW, Butler MA, Bailey JR, Young JF, Skipper PW, Tannenbaum SR (1991) Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res 51:4371–4377PubMed

11.

Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, Giovannucci EL (1999) Fluid intake and the risk of bladder cancer in men. N Engl J Med 340:1390–1397PubMedCrossRef

12.

Kang D, Chokkalingam AP, Gridley G, Nyren O, Johansson JE, Adami HO, Silverman D, Hsing AW (2007) Benign prostatic hyperplasia and subsequent risk of bladder cancer. Br J Cancer 96:1475–1479PubMedCentralPubMedCrossRef

13.

Pode D, Alon Y, Horowitz AT, Vlodavsky I, Biran S (1986) The mechanism of human bladder tumor implantation in an in vitro model. J Urol 136:482–486PubMed

14.

Soloway MS, Masters S (1980) Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46:1158–1163PubMedCrossRef

15.

Vicente J, Chechile G, Pons R, Mendez G (1988) Tumor recurrence in prostatic urethra following simultaneous resection of bladder tumor and prostate. Eur Urol 15:40–42PubMed

16.

Tsivian A, Shtricker A, Sidi AA (2003) Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? J Urol 170:2241–2243PubMedCrossRef

17.

Ugurlu O, Gonulalan U, Adsan O, Kosan M, Oztekin V, Cetinkaya M (2007) Effects of simultaneous transurethral resection of prostate and solitary bladder tumors smaller than 3 cm on oncologic results. Urology 70:55–59PubMedCrossRef

18.

Elshal AM, Elmansy HM, Elhilali MM (2013) Transurethral laser surgery for benign prostate hyperplasia in octogenarians: safety and outcomes. Urology 81:634–639PubMedCrossRef

19.

Woo H, Thangasamy I, Chalasani V (2013) Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int 111:E137PubMedCrossRef

20.

Malek RS, Kuntzman RS, Barrett DM (2005) Photoselective potassium-titanyl-phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 174:1344–1348PubMedCrossRef

21.

Mohanty NK, Vasudeva P, Kumar A, Prakash S, Jain M, Arora RP (2012) Photoselective vaporization of prostate vs. transurethral resection of prostate: a prospective, randomized study with one year follow-up. Indian J Urol 28:307–312PubMedCentralPubMedCrossRef

22.

Mosli HA, Abdel-Meguid TA, Abdulwahhab MH, Al-Sayyad A, Farsi HM, Tayib A (2013) Photoselective vaporization of the prostate using GreenLight 120-W lithium triborate laser to treat symptomatic benign prostatic hyperplasia: A single-centre prospective study. Can Urol Assoc J 7:193–196

23.

Teng J, Zhang D, Li Y, Yin L, Wang K, Cui X, Xu D (2013) Photoselective vaporization with the green light laser vs transurethral resection of the prostate for treating benign prostate hyperplasia: a systematic review and meta-analysis. BJU Int 111:312–323

24.

Zang Y, Xue B, Zhang Y, Yang D, Gao J, Sun C, Cui Y, Tao W, Chen D, Shan Y (2012) Photoselective vaporization of the prostate with GreenLight HPS 120-W laser for benign prostatic hyperplasia: 36 months’ follow-up. Urol Int 89:203–207PubMedCrossRef

25.

Hai MA, Malek RS (2003) Photoselective vaporization of the prostate: initial experience with a new 80 W KTP laser for the treatment of benign prostatic hyperplasia. J Endourol 17:93–96PubMedCrossRef

26.

Malek RS, Barrett DM, Kuntzman RS (1998) High-power potassium-titanyl-phosphate (KTP/532) laser vaporization prostatectomy: 24 hours later. Urology 51:254–256PubMedCrossRef

27.

Li J, Hou R, Zhang Z, Li Z, Zhang Y, Feng Q (2010) Curative effectiveness of GreenLight photoselective laser vaporization and electrocautery transurethral resection for superficial bladder tumors. J Clin Urol 25:586–588

28.

Liu W, Li T (2007) Photoselective vaporization for the treatment of superficial bladder cancer. Chin J Mod Med 17:2418–2420

29.

Jin C, Xu Y, Wu D, Sa Y, Chen B (2007) Potassium-titanyl-phosphate laser vaporization in the treatment of superficial bladder tumor. J Clin Urol 22:343–344

Titel: The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms
verfasst von: Zhaoyi Li
Ruipeng Hou
Jian Li
Publikationsdatum: 01.04.2014
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2014
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-013-0572-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The efficacy and safety of simultaneous transurethral GreenLight photoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Perirenal fat associated with microalbuminuria in obese rats

External extension of double-J ureteral stent during pyeloplasty: inexpensive stent and non-cystoscopic removal

Pediatric metanephric adenoma: case report and review of the literature

Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men

A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth

Comparison of erythropoietin and sildenafil protective role against ischemia/reperfusion injury of the testis in adult rats

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin